No Script

Please Wait...

Hajj 2021

 

AstraZeneca, Pfizer Vaccines Effective against Delta COVID-19

AstraZeneca, Pfizer Vaccines Effective against Delta COVID-19
folder_openInternational News access_timeone month ago
starAdd to favorites

By Staff, Agencies 

COVID-19 vaccines made by AstraZeneca and the Pfizer-BioNTech alliance remain broadly effective against Delta and Kappa variants of the COVID-19 causing virus, which were first identified in India, according to a scientific study, underpinning a continued push to deliver the shots.

The study by Oxford University researchers, published in the journal Cell, investigated the ability of antibodies in the blood from people, who were vaccinated with the two-shot regimens, to neutralize the highly contagious Delta and Kappa variants, a statement said.

"There is no evidence of widespread escape suggesting that the current generation of vaccines will provide protection against the B.1.617 lineage," the paper said, referring to the Delta and Kappa variants by a commonly used code.

However, the concentration of neutralizing antibodies in the blood was somewhat reduced, which may lead to some breakthrough infections, they cautioned.

Last week, an analysis by the Public Health England [PHE] showed that vaccines made by Pfizer Inc and AstraZeneca offer high protection of more than 90% against hospitalization from the Delta variant.

The Delta variant is becoming the globally dominant version of the disease, the World Health Organization's chief scientist said on Friday.

The Oxford researchers also analyzed reinfection patterns in people who had previously had COVID-19. The risk of reinfection with the Delta variant appeared particularly high in individuals previously infected by the Beta and Gamma lineages that emerged in South Africa and Brazil, respectively.

Comments